Evidence map›Paper›PMID 39417342›Full record

ArticleImmunotherapy2024

Hemophagocytic lymphohistiocytosis in a patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.

Ana Maria Meireles, Gloria Iacoboni, Leonardo Maia Moço, Inês Ramos, Gil Brás, Júlia Azevedo, Ângelo Rodrigues, Cláudia Moreira, Mário Mariz

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ana Maria MeirelesDepartment of Hematology & Bone Marrow Transplantation of Instituto Português de Oncologia do Porto, E.P.E (IPO-Porto), 04200, Porto, Portugal.ORCID 0000-0002-6465-1174
Gloria IacoboniDepartment of Pathological Anatomy of IPO-Porto, 04200, Porto, Portugal.
Leonardo Maia MoçoDepartment of Hematology & Bone Marrow Transplantation of Instituto Português de Oncologia do Porto, E.P.E (IPO-Porto), 04200, Porto, Portugal.ORCID 0000-0003-2544-4030
Inês RamosDepartment of Hematology & Bone Marrow Transplantation of Instituto Português de Oncologia do Porto, E.P.E (IPO-Porto), 04200, Porto, Portugal.
Gil BrásDepartment of Hematology & Bone Marrow Transplantation of Instituto Português de Oncologia do Porto, E.P.E (IPO-Porto), 04200, Porto, Portugal.
Júlia AzevedoDepartment of Pathological Anatomy of IPO-Porto, 04200, Porto, Portugal.
Ângelo RodriguesDepartment of Pathological Anatomy of IPO-Porto, 04200, Porto, Portugal.
Cláudia MoreiraDepartment of Hematology & Bone Marrow Transplantation of Instituto Português de Oncologia do Porto, E.P.E (IPO-Porto), 04200, Porto, Portugal.
Mário MarizDepartment of Hematology & Bone Marrow Transplantation of Instituto Português de Oncologia do Porto, E.P.E (IPO-Porto), 04200, Porto, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the advent of chimeric antigen receptors T-cell therapy, understanding their role in the development of hemophagocytic lymphohistiocytosis has become increasingly complex. We describe a case of a young patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma, who was treated with axicabtagene ciloleucel. The patient developed progressive cytopenia and, on Day 73 post-infusion, met criteria for hemophagocytic lymphohistiocytosis. Bone marrow evaluation revealed hemophagocytosis without evidence of clonal B cells. The patient was treated with tocilizumab, dexamethasone, etoposide and anakinra, which eventually led to improvement. Unfortunately, the patient succumbed to an infection. Disease progression was confirmed posthumously.This case report explores the differential diagnosis of hyperinflammatory syndromes following chimeric antigen receptor T-cell therapy and highlights the reduced efficacy of this treatment in patients with a T-cell/histiocyte-rich background.

Indexed as

Epstein-Barr Virus InfectionsHerpesvirus 4, HumanImmunotherapy, AdoptiveLymphohistiocytosis, HemophagocyticLymphoma, Large B-Cell, DiffuseReceptors, Chimeric AntigenBiological ProductsFatal OutcomeHumansaxicabtagene ciloleucelBiological ProductsReceptors, Chimeric AntigenCAR t-cell therapyEpstein–Barr virus-positive large B-cell lymphomahemophagocytic lymphohistiocytosisimmune effector cell-associated hemophagocytic lymphohistiocytosis-like syndromepost immune effector cells hyperinflammatory syndromes

Identifiers

PMID39417342
PMCPMC11633410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.